Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Treatment for atrial fibrillation was initiated, including rate control and anticoagulation with 5 mg of apixaban two times per day for primary stroke prophylaxis. Three days after initiation of ...

With the emergence and approval of other new oral anticoagulants such as dabigatran and rivaroxaban, the role of and place in therapy for all of these new agents will have to be clearly delineated.

Major/CRNM bleeding occurred in 169 (4.05%/year) and 210 (5.34%/year) patients in the apixaban and warfarin groups, respectively. The efficacy and safety of apixaban compared with warfarin as assessed ...

Participants with device-detected subclinical atrial fibrillation lasting from 6 minutes to 24 hours, and a CHA2DS2-VASc score of 3 or higher, were randomly assigned to receive either 5 mg of apixaban ...

In the apixaban group, 5.1% of participants experienced incident covert infarcts ... apixaban over other treatments in this high-risk population. Reference: Lansberg MG et al. Apixaban to Prevent ...

His medical history revealed hypertension, type 2 diabetes mellitus and paroxysmal atrial fibrillation, for which he had been prescribed oral doses of 80 mg/day of telmisartan, 1000 mg/day of ...